A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge

Anaplasma marginale is the most prevalent tick-borne livestock pathogen with worldwide distribution. Bovine anaplasmosis is a significant threat to cattle industry. Anaplasmosis outbreaks in endemic areas are prevented via vaccination with live A. centrale produced in splenectomized calves. Since A. centrale live vaccine can carry other pathogens and cause disease in adult cattle, research efforts are directed to develop safe recombinant subunit vaccines. Previous work found that the subdominant proteins of A. marginale type IV secretion system (T4SS) and the subdominant elongation factor-Tu (Ef-Tu) were involved in the protective immunity against the experimental challenge in cattle immunized with the A. marginale outer membrane (OM). This study evaluated the immunogenicity and protection conferred by recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins cloned and expressed in E. coli. Twenty steers were randomly clustered into four groups (G) of five animals each. Cattle from G1 and G2 were immunized with a mixture of 50 μg of each recombinant protein with Quil A® or Montanide™ adjuvants, respectively. Cattle from G3 and G4 (controls) were immunized with Quil A and Montanide adjuvants, respectively. Cattle received four immunizations at three-week intervals and were challenged with 107 A. marginale-parasitized erythrocytes 42 days after the fourth immunization. After challenge, all cattle showed clinical signs, with a significant drop of packed cell volume and a significant increase of parasitized erythrocytes (p<0.05), requiring treatment with oxytetracycline to prevent death. The levels of IgG2 induced in the immunized groups did not correlate with the observed lack of protection. Additional strategies are required to evaluate the role of these proteins and their potential utility in the development of effective vaccines.

Saved in:
Bibliographic Details
Main Authors: Sarli, Macarena, Novoa, María Belen, Mazzucco, Matilde N., Signorini, Marcelo, Echaide, Ignacio Eduardo, Echaide, Susana T. de, Primo, María Evangelina
Format: info:ar-repo/semantics/artículo biblioteca
Language:eng
Published: PLOS; National Center for Biotechnology Information 2020-02
Subjects:Anaplasma Marginale, Vacuna, Proteínas Recombinantes, Virulencia, Vaccines, Recombinant Proteins, Virulence,
Online Access:http://hdl.handle.net/20.500.12123/6996
https://pubmed.ncbi.nlm.nih.gov/32084216/
https://doi.org/10.1371/journal.pone.0229301
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:localhost:20.500.12123-6996
record_format koha
spelling oai:localhost:20.500.12123-69962020-03-27T14:16:52Z A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge Sarli, Macarena Novoa, María Belen Mazzucco, Matilde N. Signorini, Marcelo Echaide, Ignacio Eduardo Echaide, Susana T. de Primo, María Evangelina Anaplasma Marginale Vacuna Proteínas Recombinantes Virulencia Vaccines Recombinant Proteins Virulence Anaplasma marginale is the most prevalent tick-borne livestock pathogen with worldwide distribution. Bovine anaplasmosis is a significant threat to cattle industry. Anaplasmosis outbreaks in endemic areas are prevented via vaccination with live A. centrale produced in splenectomized calves. Since A. centrale live vaccine can carry other pathogens and cause disease in adult cattle, research efforts are directed to develop safe recombinant subunit vaccines. Previous work found that the subdominant proteins of A. marginale type IV secretion system (T4SS) and the subdominant elongation factor-Tu (Ef-Tu) were involved in the protective immunity against the experimental challenge in cattle immunized with the A. marginale outer membrane (OM). This study evaluated the immunogenicity and protection conferred by recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins cloned and expressed in E. coli. Twenty steers were randomly clustered into four groups (G) of five animals each. Cattle from G1 and G2 were immunized with a mixture of 50 μg of each recombinant protein with Quil A® or Montanide™ adjuvants, respectively. Cattle from G3 and G4 (controls) were immunized with Quil A and Montanide adjuvants, respectively. Cattle received four immunizations at three-week intervals and were challenged with 107 A. marginale-parasitized erythrocytes 42 days after the fourth immunization. After challenge, all cattle showed clinical signs, with a significant drop of packed cell volume and a significant increase of parasitized erythrocytes (p<0.05), requiring treatment with oxytetracycline to prevent death. The levels of IgG2 induced in the immunized groups did not correlate with the observed lack of protection. Additional strategies are required to evaluate the role of these proteins and their potential utility in the development of effective vaccines. EEA Rafaela Fil: Sarli, Macarena. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fil: Novoa, María Belen. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fil: Mazzucco, Matilde N. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Fil: Signorini, Marcelo. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fil: Echaide, Ignacio Eduardo. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Fil: Echaide, Susana T. de. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Fil: Primo, María Evangelina. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. 2020-03-27T14:02:26Z 2020-03-27T14:02:26Z 2020-02 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/6996 https://pubmed.ncbi.nlm.nih.gov/32084216/ 1932-6203 https://doi.org/10.1371/journal.pone.0229301 eng info:eu-repo/semantics/openAccess application/pdf PLOS; National Center for Biotechnology Information PLoS One 15 (2) : e0229301. (2020 Feb 21)
institution INTA AR
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-inta-ar
tag biblioteca
region America del Sur
libraryname Biblioteca Central del INTA Argentina
language eng
topic Anaplasma Marginale
Vacuna
Proteínas Recombinantes
Virulencia
Vaccines
Recombinant Proteins
Virulence
Anaplasma Marginale
Vacuna
Proteínas Recombinantes
Virulencia
Vaccines
Recombinant Proteins
Virulence
spellingShingle Anaplasma Marginale
Vacuna
Proteínas Recombinantes
Virulencia
Vaccines
Recombinant Proteins
Virulence
Anaplasma Marginale
Vacuna
Proteínas Recombinantes
Virulencia
Vaccines
Recombinant Proteins
Virulence
Sarli, Macarena
Novoa, María Belen
Mazzucco, Matilde N.
Signorini, Marcelo
Echaide, Ignacio Eduardo
Echaide, Susana T. de
Primo, María Evangelina
A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge
description Anaplasma marginale is the most prevalent tick-borne livestock pathogen with worldwide distribution. Bovine anaplasmosis is a significant threat to cattle industry. Anaplasmosis outbreaks in endemic areas are prevented via vaccination with live A. centrale produced in splenectomized calves. Since A. centrale live vaccine can carry other pathogens and cause disease in adult cattle, research efforts are directed to develop safe recombinant subunit vaccines. Previous work found that the subdominant proteins of A. marginale type IV secretion system (T4SS) and the subdominant elongation factor-Tu (Ef-Tu) were involved in the protective immunity against the experimental challenge in cattle immunized with the A. marginale outer membrane (OM). This study evaluated the immunogenicity and protection conferred by recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins cloned and expressed in E. coli. Twenty steers were randomly clustered into four groups (G) of five animals each. Cattle from G1 and G2 were immunized with a mixture of 50 μg of each recombinant protein with Quil A® or Montanide™ adjuvants, respectively. Cattle from G3 and G4 (controls) were immunized with Quil A and Montanide adjuvants, respectively. Cattle received four immunizations at three-week intervals and were challenged with 107 A. marginale-parasitized erythrocytes 42 days after the fourth immunization. After challenge, all cattle showed clinical signs, with a significant drop of packed cell volume and a significant increase of parasitized erythrocytes (p<0.05), requiring treatment with oxytetracycline to prevent death. The levels of IgG2 induced in the immunized groups did not correlate with the observed lack of protection. Additional strategies are required to evaluate the role of these proteins and their potential utility in the development of effective vaccines.
format info:ar-repo/semantics/artículo
topic_facet Anaplasma Marginale
Vacuna
Proteínas Recombinantes
Virulencia
Vaccines
Recombinant Proteins
Virulence
author Sarli, Macarena
Novoa, María Belen
Mazzucco, Matilde N.
Signorini, Marcelo
Echaide, Ignacio Eduardo
Echaide, Susana T. de
Primo, María Evangelina
author_facet Sarli, Macarena
Novoa, María Belen
Mazzucco, Matilde N.
Signorini, Marcelo
Echaide, Ignacio Eduardo
Echaide, Susana T. de
Primo, María Evangelina
author_sort Sarli, Macarena
title A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge
title_short A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge
title_full A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge
title_fullStr A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge
title_full_unstemmed A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge
title_sort vaccine using anaplasma marginale subdominant type iv secretion system recombinant proteins was not protective against a virulent challenge
publisher PLOS; National Center for Biotechnology Information
publishDate 2020-02
url http://hdl.handle.net/20.500.12123/6996
https://pubmed.ncbi.nlm.nih.gov/32084216/
https://doi.org/10.1371/journal.pone.0229301
work_keys_str_mv AT sarlimacarena avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT novoamariabelen avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT mazzuccomatilden avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT signorinimarcelo avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT echaideignacioeduardo avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT echaidesusanatde avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT primomariaevangelina avaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT sarlimacarena vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT novoamariabelen vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT mazzuccomatilden vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT signorinimarcelo vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT echaideignacioeduardo vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT echaidesusanatde vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
AT primomariaevangelina vaccineusinganaplasmamarginalesubdominanttypeivsecretionsystemrecombinantproteinswasnotprotectiveagainstavirulentchallenge
_version_ 1756007721272868865